Netilmicin

Netilmicin
Clinical data
Trade names	Netromycin
Other names	1-N-Ethylsisomicin
AHFS/Drugs.com	Monograph
MedlinePlus	a605011
Routes of; administration	Topical
ATC code	J01GB07 (WHO) S01AA23 (WHO);
Legal status
Legal status	CA: ℞-only; UK: POM (Prescription only);
Pharmacokinetic data
Bioavailability	~0%
Elimination half-life	2.5 hours
Identifiers
	IUPAC name (2R,3R,4R,5R)-2-{[(1S,2S,3R,4S,6R)-4-Amino-3-{[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy}-6-(ethylamino)-2-hydroxycyclohexyl]oxy}-5-methyl-4-(methylamino)oxane-3,5-diol;
CAS Number	56391-56-1 ;
PubChem CID	41859;
DrugBank	DB00955 ;
ChemSpider	38195 ;
UNII	4O5J85GJJB;
KEGG	D08268 ;
ChEMBL	ChEMBL1572 ;
CompTox Dashboard (EPA)	DTXSID1048542 ;
ECHA InfoCard	100.054.661
Chemical and physical data
Formula	C21H41N5O7
Molar mass	475.587 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O[C@]3(C)[C@H](NC)[C@@H](O)[C@@H](O[C@H]2[C@H](NCC)C[C@H](N)[C@@H](OC1O\C(=C/CC1N)CN)[C@@H]2O)OC3;
	InChI InChI=1S/C21H41N5O7/c1-4-26-13-7-12(24)16(32-19-11(23)6-5-10(8-22)31-19)14(27)17(13)33-20-15(28)18(25-3)21(2,29)9-30-20/h5,11-20,25-29H,4,6-9,22-24H2,1-3H3/t11?,12-,13+,14-,15+,16+,17-,18+,19?,20+,21-/m0/s1 ; Key:CIDUJQMULVCIBT-KALHTFJLSA-N ;
	(what is this?) (verify)

Netilmicin (1-N-ethylsisomicin) is a semisynthetic aminoglycoside antibiotic, and a derivative of sisomicin, produced by Micromonospora inyoensis. Aminoglycoside antibiotics have the ability to kill a wide variety of bacteria. Netilmicin is not absorbed from the gut and is therefore only given by injection or infusion. It is only used in the treatment of serious infections particularly those resistant to gentamicin.

It was patented in 1973 and approved for medical use in 1981. It was approved for medical use in the UK in December 2019, for the treatment of external infections of the eye. It is on the World Health Organization's List of Essential Medicines.